FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical...
HOUSTON, Dec. 17, 2019 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced the completed good...
TAIPEI, Taiwan, Dec. 18, 2019 /PRNewswire/ — OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced the initiation of a Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT04084366) of OBI-999, an antibody drug conjugate (ADC) targeting...
LUND, Sweden, Dec. 18, 2019 /PRNewswire/ — BioInvent International AB (“BioInvent” or the “Company”) (OMXS: BINV) today announces that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney Disease (CKD). This study is designed to investigate the safety,...
Email
Text